These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37933640)

  • 1. [High expression of secretogranin II increases oxaliplatin resistance of colorectal cancer cells].
    Deng J; Pan T; Zhou G; Gao Y; Peng W; Wei W; Lü C
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Oct; 43(10):1657-1664. PubMed ID: 37933640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretogranin II impairs tumor growth and angiogenesis by promoting degradation of hypoxia-inducible factor-1α in colorectal cancer.
    Fang C; Dai L; Wang C; Fan C; Yu Y; Yang L; Deng H; Zhou Z
    Mol Oncol; 2021 Dec; 15(12):3513-3526. PubMed ID: 34160138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCG2 is a Prognostic Biomarker Associated With Immune Infiltration and Macrophage Polarization in Colorectal Cancer.
    Wang H; Yin J; Hong Y; Ren A; Wang H; Li M; Zhao Q; Jiang C; Liu L
    Front Cell Dev Biol; 2021; 9():795133. PubMed ID: 35047505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casein Kinase 2α Augments Oxaliplatin Resistance in Colorectal Cancer Cells by Increasing ABCE1 Expression.
    Yun CW; Lee JH; Lee SH
    Anticancer Res; 2023 Jun; 43(6):2519-2525. PubMed ID: 37247928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intense endoplasmic reticulum stress (ERS) / IRE1α enhanced Oxaliplatin efficacy by decreased ABCC10 in colorectal cancer cells.
    Liu X; Wu B; Chen H; Sun H; Guo X; Sun T; Zhou D; Yang S
    BMC Cancer; 2022 Dec; 22(1):1369. PubMed ID: 36585626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCG2: A Prognostic Marker That Pinpoints Chemotherapy and Immunotherapy in Colorectal Cancer.
    Weng S; Liu Z; Ren X; Xu H; Ge X; Ren Y; Zhang Y; Dang Q; Liu L; Guo C; Beatson R; Deng J; Han X
    Front Immunol; 2022; 13():873871. PubMed ID: 35844556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
    Li J; Lv J; Chen Y; Li L
    Gene; 2023 May; 864():147323. PubMed ID: 36858188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin.
    Zhang YJ; Li AJ; Han Y; Yin L; Lin MB
    World J Gastroenterol; 2014 Jul; 20(25):8229-36. PubMed ID: 25009397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
    Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
    Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Reovirus-Specific and Herpesvirus-Specific Activator Protein 1 Activation of Secretogranin II Leads to Altered Virus Secretion.
    Berard AR; Severini A; Coombs KM
    J Virol; 2015 Dec; 89(23):11954-64. PubMed ID: 26378181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretogranin II binds to secretogranin III and forms secretory granules with orexin, neuropeptide Y, and POMC.
    Hotta K; Hosaka M; Tanabe A; Takeuchi T
    J Endocrinol; 2009 Jul; 202(1):111-21. PubMed ID: 19357184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
    Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
    Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
    Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
    Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.